Your browser doesn't support javascript.
Hiv and Chronic Comorbidities: Medication Adherence and Clinical Endpoint Covariation
Topics in Antiviral Medicine ; 31(2):357, 2023.
Article in English | EMBASE | ID: covidwho-2317249
ABSTRACT

Background:

Evidence suggests negative monthly medication adherence trends during the COVID-19 era for patients with HIV (PWH) and multiple chronic conditions. However, it is unknown whether observed trends are associated with changes in outcomes of HIV care before and during the COVID-19 era. Method(s) Adult PWH with type 2 diabetes, hypertension, and/or hypercholesterolemia were identified in a US mid-Atlantic integrated health system. Multivariable population-averaged panel general estimating equations were used to assess the relationship between medication adherence [i.e., accepted dichotomous thresholds for optimal proportion of days covered (PDC)] for four medication groups antiretrovirals [ART], diabetes medications [DMs], renin-angiotensin antagonists [RASMs], and statins [SMs] and their related clinical endpoints [i.e., viral load (VL;copies/mL), HbA1c, systolic and diastolic blood pressure (SBP, DBP;mmHg), and total cholesterol (TC;mg/dl)] during a 37-month longitudinal observation period [9/2018-9/2021]. Covariates included demographics, number of medication groups, COVID-19 era (starting 3/1/2020), and a COVID-19/PDC interaction term. Result(s) The cohort [n=543] was predominantly 51-64y [59.30%], Black [73.11%], male [69.24%], and privately insured [65.38%]. All patients were prescribed ART with 75.32% co-prescribed SMs;followed by RASMs [42.73%];and DMs [25.60%]. ART PDC>=0.9 was associated with decreased odds of VL>=200 copies/mL [aOR=0.77, 95% CI 0.63-0.94]. For DMs, RASMs and SMS, PDC>=0.8 was not associated with the clinical endpoints of HbA1c>=7.0% [aOR=0.99, 95% CI 0.94-1.04], SBP>=130 mmHg [aOR=1.03;95% CI 0.93-1.14], DBP>=80 mmHg [aOR=1.05, 95% CI 0.94-1.16] or TC>=200 mg/dl [aOR=1.00, 95% CI 0.96-1.04], respectively. The COVID-19 era [3/2020 to 9/2021] was associated with increased odds of SBP>=130 [aOR=1.22, 95% CI 1.01-1.48], but not for DBP>=80 mmHg [aOR=1.05, 95% CI 0.85-1.28], VL>=200 copies/ mL [aOR=1.01, 95% CI 0.67-1.52], HbA1c>=7.0% [aOR=0.99, 95% CI 0.88-1.11], and TC>=200 mg/dl [aOR=0.95, 95% CI 0.86-1.04]. No interactions between COVID-19 era and PDC on clinical endpoints were observed. Conclusion(s) ART adherence was associated with viral suppression in PWH, but there were no observed associations between DM, RASM, and SM adherence and their respective clinical endpoints. With the exception of a direct relationship between the COVID-19 start date and SBP, the COVID-19 era was not associated with variations in VL, HbA1c, DBP, and TC clinical endpoints.
Keywords
Search on Google
Collection: Databases of international organizations Database: EMBASE Type of study: Prognostic study Language: English Journal: Topics in Antiviral Medicine Year: 2023 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Collection: Databases of international organizations Database: EMBASE Type of study: Prognostic study Language: English Journal: Topics in Antiviral Medicine Year: 2023 Document Type: Article